

A multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the use of Chinese herbal medicine in the management of endometriosis: a prospective study

Submission date 04/05/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 02/06/2006	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 20/09/2007	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Alex Liew

Contact details

497 South Road
Ashford
South Australia
Australia
5035
+61 (0)8 83713711
endoherb@tpg.com.au

Additional identifiers

Protocol serial number

HEC 02/098

Study information

Scientific Title

Acronym

Endoherb

Study objectives

The hypothesis is that the formulated Chinese herbal treatment shows no significant difference than a placebo in the management of the symptoms of endometriosis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the University of Western Sydney's Ethics Committee on the 8th August 2002 (ref: HEC 02/098).

Study design

A multicentre, randomised, double-blind, placebo-controlled clinical trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Endometriosis

Interventions

A specific Chinese herbal formula (Endoherb) versus placebo.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Endoherb

Primary outcome(s)

Pain intensity due to endometriosis, measured quantitatively on the VAS and qualitatively as descriptive values.

Key secondary outcome(s))

1. Quality of life using the 36-item Short-Form health survey (SF-36) and a study design health survey tool
2. Serum CA 125 levels

Completion date

15/11/2005

Eligibility

Key inclusion criteria

1. Women, aged 18 - 43 years
2. Diagnosed with endometriosis by laparoscopy and the severity staged (grade I - IV)
3. At least three months of pain measuring more than 30 mm on visual analogue scale (VAS) scale

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Key exclusion criteria

1. Menopause
2. Pregnancy
3. Liver diseases
4. Suffering from diabetes mellitus
5. Suffering from malignancies
6. Hormonal treatments
7. Anti-depressant treatments
8. Immunosuppressive conditions and treatments

Date of first enrolment

15/11/2004

Date of final enrolment

15/11/2005

Locations

Countries of recruitment

Australia

Study participating centre
497 South Road
South Australia
Australia
5035

Sponsor information

Organisation
University of Western Sydney (Australia)

ROR
<https://ror.org/03t52dk35>

Funder(s)

Funder type
University/education

Funder Name
University of Western Sydney (Australia)

Alternative Name(s)
UWS

Funding Body Type
Private sector organisation

Funding Body Subtype
Universities (academic only)

Location
Australia

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration